Clinical Trial: Correlation of Serum CA19-9 Levels With Levels in Saliva and Urine of Patients With Ductal Adenocarcinoma of the Pancreas

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: Correlation of Serum CA19-9 Levels With Levels in Saliva and Urine of Patients With Ductal Adenocarcinoma of the Pancreas

Brief Summary:

Ductal adenocarcinoma of the pancreas is the fifth leading cause of cancer related deaths in the European Union. Tumor markers CA19-9 and carcinoembryonic antigen are important components in decision making and follow-up of patients diagnosed with this disease.

These tumor markers were found to be elevated not only in the serum but also in other body fluids in patients with malignant lesions of the parotid gland and the urinary tract. The authors have described in a previews small preliminary study a positive and a strong linear correlation between the levels of CA19-9 in urine and saliva with those presented in the serum of patients with ductal adenocarcinoma of the pancreas. The current study seeks to enlarge the study population to confirm the previous results and standardize the measured levels of CA19-9 in these body fluids.

Detailed Summary:
Sponsor: Rambam Health Care Campus

Current Primary Outcome: correlation of CA19-9 levels in urine and saliva with those in the serum [ Time Frame: 1 year ]

Original Primary Outcome: Same as current

Current Secondary Outcome: Number of participants needed to standardize the measurements in urine and saliva according to those measured in the serum. [ Time Frame: 1 year ]

Original Secondary Outcome: Same as current

Information By: Rambam Health Care Campus

Dates:
Date Received: February 10, 2016
Date Started: July 2016
Date Completion: April 2018
Last Updated: October 5, 2016
Last Verified: October 2016